珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
2026年10月08日 23:40:12来源:作者:
【摘要】 New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents wit

New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1
The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least 75% improvement in eczema severity, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life at Week 1521
Additional analyses to be presented further establish itch and skin lesions as central drivers of sleep disturbance and overall quality of life impairment in prurigo nodularis and atopic dermatitis2,3
Collectively, these data reinforce our understanding of the long-term efficacy and safety profile of Nemluvio and underscore Galderma's long-standing commitment to improving the outcomes that matter most to patients with atopic dermatitis and prurigo nodularis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator.

 

“These three-year data provide important evidence of the long-term impact of Nemluvio, showing that improvements with Nemluvio were not only achieved but sustained over time, with durable benefits observed across skin symptoms, itch, sleep disturbance and quality of life. Coupled with a well-characterized safety profile, these findings add to the robust and growing body of evidence regarding the long-term use of Nemluvio in moderate-to-severe atopic dermatitis.”

 

PROFESSOR JONATHAN SILVERBERG
LEAD INVESTIGATOR OF THE ARCADIA CLINICAL PROGRAM, PROFESSOR OF DERMATOLOGY, GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES, UNITED STATES

 

 

责任编辑: admin

看新闻,关注新闻

本网网友:浅笑含双靥╮
评论:我要多念一点书,哪怕以后当流氓,那咱也是有文化的流氓。

搜狐网友:经年°reminis
评论:八戒,别以为你站在路灯下就是夜明猪了

凤凰网友:心不亡wenod∕
评论:你玩儿的叫潜水,哥玩儿的叫潜伏

天涯网友:一个2B的男人
评论:黄瓜是用来拍的,人生是用来嗨的

猫扑网友:念旧-  Tender
评论:儿子要穷养,长大了才知道奋斗;女儿要富教,长大了才不会被诱惑。

网易网友:自戀的病源
评论:这世界上最爱我的男人,早已经从了妈妈。

百度网友:目标锁定 Against
评论:恋爱需要实习,分手需要练习。

腾讯网友:跟你逃离uniVer
评论:哥,不寂寞。因为有寂寞陪着哥。

淘宝网友:没感觉  End.ゝ
评论:食堂一直是个大问题 最近越来越怀疑那些食堂的人究竟是炊事员还是饲养员 ...

天猫网友:永远 ▍ Forever°
评论:昨天去市里参加放鸽子比赛,结果就我一个人去了。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!